Cure My Disease

Don't miss your cure!

 Log in / Sign up

Post-Market watch: tracking side effects of cancer drug in real patients

NCT ID NCT05844332

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study aimed to monitor the safety of the drug LUTATHERA after it was approved for use. It observed 347 patients with a specific type of neuroendocrine tumor who received the drug in real-world medical settings. The main goal was to track the occurrence of certain serious side effects, like kidney problems and blood disorders, to better understand the drug's safety profile outside of controlled clinical trials.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOMATOSTATIN RECEPTOR-POSITIVE NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 464 8681, Japan

  • Novartis Investigative Site

    Hirosaki, Aomori, 036 8563, Japan

  • Novartis Investigative Site

    Kamogawa, Chiba, 296-8602, Japan

  • Novartis Investigative Site

    Kashiwa, Chiba, 277 8577, Japan

  • Novartis Investigative Site

    Tōon, Ehime, 7910295, Japan

  • Novartis Investigative Site

    Fukui-shi, Fukui, 910-8526, Japan

  • Novartis Investigative Site

    Gifu, Gifu, 501-1194, Japan

  • Novartis Investigative Site

    Maebashi, Gunma, 371 8511, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 060 8648, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 608543, Japan

  • Novartis Investigative Site

    Akashi, Hyōgo, 673-8558, Japan

  • Novartis Investigative Site

    Kobe, Hyōgo, 6500047, Japan

  • Novartis Investigative Site

    Kanazawa, Ishikawa-ken, 920 8641, Japan

  • Novartis Investigative Site

    Kita-gun, Kagawa-ken, 7610793, Japan

  • Novartis Investigative Site

    Kagoshima, Kagoshima-ken, 890 8520, Japan

  • Novartis Investigative Site

    Kamakura, Kanagawa, 247-8533, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa-ku, 236-0004, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 980 8574, Japan

  • Novartis Investigative Site

    Suwa, Nagano, 392-8510, Japan

  • Novartis Investigative Site

    Niigata, Niigata, 951-8566, Japan

  • Novartis Investigative Site

    Kurashiki, Okayama-ken, 7108602, Japan

  • Novartis Investigative Site

    Osaka, Osaka, 5418567, Japan

  • Novartis Investigative Site

    Osaka, Osaka, 553-0003, Japan

  • Novartis Investigative Site

    Sakai, Osaka, 590-0197, Japan

  • Novartis Investigative Site

    Suita, Osaka, 565 0871, Japan

  • Novartis Investigative Site

    Hamamatsu, Shizuoka, 4313192, Japan

  • Novartis Investigative Site

    Iwata, Shizuoka, 438-8550, Japan

  • Novartis Investigative Site

    Shizuoka, Shizuoka, 420-8527, Japan

  • Novartis Investigative Site

    Sunto Gun, Shizuoka, 411 8777, Japan

  • Novartis Investigative Site

    Tokushima, Tokushima, 7708503, Japan

  • Novartis Investigative Site

    Bunkyo-ku, Tokyo, 1138519, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 104 0045, Japan

  • Novartis Investigative Site

    Koto Ku, Tokyo, 135 8550, Japan

  • Novartis Investigative Site

    Toyama, Toyama, 9300194, Japan

  • Novartis Investigative Site

    Yamagata, Yamagata, 990 9585, Japan

  • Novartis Investigative Site

    Chūō, Yamanashi, 409-3898, Japan

  • Novartis Investigative Site

    Chiba, 260-8717, Japan

  • Novartis Investigative Site

    Fukuoka, 8128582, Japan

  • Novartis Investigative Site

    Fukuoka, 814-0001, Japan

  • Novartis Investigative Site

    Fukushima, 960 1295, Japan

  • Novartis Investigative Site

    Hiroshima, 7348551, Japan

  • Novartis Investigative Site

    Kobe, 650-0017, Japan

  • Novartis Investigative Site

    Kumamoto, 860-8556, Japan

  • Novartis Investigative Site

    Kyoto, 606 8507, Japan

  • Novartis Investigative Site

    Okayama, 7008558, Japan

  • Novartis Investigative Site

    Osaka, 5458586, Japan

Conditions

Explore the condition pages connected to this study.

SOMATOSTATIN RECEPTOR-POSITIVE NEUROENDOCRINE TUMOR